Diabetic ketoacidosis is usually associated with type 1 diabetes; however, it is increasingly being recognised in type 2 diabetes. The three main mechanisms suggested are: insulinopaenia, elevation in counter-regulatory hormones as a stress response, and increase in free fatty acids. This review aims to highlight the mechanism of diabetic ketoacidosis in type 2 diabetes, the difference compared...

Acute renal failure (ARF) is a serious condition which still carries a mortality of around 50%. People with diabetes may be at increased risk of developing ARF, either as a complication of diabetic ketoacidosis or hyperosmolar coma, increased incidence of cardiovascular disease, or due to increased susceptibility of the kidney to adverse effects in the presence of underlying diabetic renal dise...

Diabetic ketoacidosis is a major cause of morbidity and mortality in patients with insulin dependent diabetes. Myocardial infarction is an uncommon but well-recognised precipitating cause of diabetic ketoacidosis, accounting for 1% of cases. Many diabetic patients with ketoacidosis initially present with hyperkelamia, which may affect the electrocardiographic morphology. We present a patient wi...

AIM The aim of this study was to evaluate the incidence of diabetic ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes in 2006-2007 and 2013-2014. METHOD The study group consisted of 426 children aged 0-18 years with type 1 diabetes onset admitted to our hospital in 2006-2007 (group A) and 2013-2014 (group B). The study comprised the analysis of medical and laborato...

Programmed cell death-1 (PD-1), an immunoreceptor, is located on T cells and pro-B cells and interacts with its ligands to inhibit T cell activation and proliferation, thereby promoting immunological self-tolerance. Nivolumab, an anti-PD1 antibody, blocks PD-1 and can restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition. Autoimmune adverse events are expecte...

OBJECTIVE Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes. METHODS We describe a case in which a patient experienced difficult-to-treat metabolic ketoacidosis in the setting of canagliflozin use. RESULTS A 52-year-old man with type 2 diabetes mellitus developed prof...

Type 1 diabetes mellitus is caused by a lack of insulin that results from the autoimmune destruction of the pancreatic beta-cells. Severe diabetes, if not controlled by periodic insulin injections, can lead to ketoacidosis and death. We have previously shown that sustained low level production of insulin in the liver of diabetic rats prevented their death from complications of diabetes. To test...

Diabetes mellitus is a worldwide disease that leads to several acute complications including diabetic ketoacidosis, hyperosmolar hyperglycemia, and hypoglycemia. In addition, diabetes causes many chronic complications that lead to debilitation and diminished quality of life. Diabetic ketoacidosis is one of the serious acute complications; however, it is usually preceded by infection, acute myoc...

Diabetic ketoacidosis is a medical emergency with somatic and psychological implications in patients with type 1 diabetes mellitus (DM1). Menstrual cycle-related glycemic change is rarely described as a precipitant of diabetic ketoacidosis. We present a case of a 23-year-old female with a history of DM1, on her second day of menstruation, who presents with diabetic ketoacidosis. In absence of o...

BACKGROUND Diabetic ketoacidosis is the most common hyperglycaemic emergency in patients with diabetes mellitus, especially type 1 diabetes. It carries very high mortality in sub-Saharan Africa, both in the treated patients and those who are presenting to hospital with diabetes for the first time. OBJECTIVE To review the risk factors, mechanisms and management approaches in diabetes ketoacido...